Alteminostat - ≥98% , CAS No.1246374-97-9

CAS: 1246374-97-9 Cat. No.: A651478 Molecular Weight: 492.61 PubChem CID: 58074180

GRADE & PURITY ≥98%

Storage

Protected from light,Store at -20°C

Shipped In

Ice chest + Ice pads

Overview

Alteminostat (CKD-581) is a potent HDAC inhibitor. Alteminostat inhibits the class I-II HDAC family via histone H3 and tubulin acetylation. Alteminostat can be used for lymphoma and multiple myeloma research.

In Vitro

Alteminostat (CKD-581; 1 nM-10 μM; 72 hours) treatment potently reduces cell viability in all four lymphoma cell lines in a concentration-dependent manner. The IC50 values of Alteminostat in SU-DHL-4, OCI-LY1, SU-DHL-2, and U2932 cells are 1.31 nM, 36.91 nM, 1.18 nM, and 31.99 nM, respectively. Alteminostat (CKD-581; 10-300 nM; 24 hours) treatment decreases the expression of BCL-6 as well as BCL-2 in cells. Alteminostat (CKD-581; 30-300 nM; 24 h) treatment results in γH2AX accumulation and PARP1 cleavage in SU-DHL-4, OCI-LY1, SU-DHL-2, and U2932 cells. Alteminostat decreases the protein levels of BCL-XL and MCL-1 in a concentration-dependent manner in OCI-LY1 cells. Alteminostat (CKD-581; 10-300 nM; 6 hours) treatment increases the acetylation of histone H3 in SU-DHL-2 cells. And tubulin acetylation also increased with 10 nM CKD-581. CKD-581 increased the acetylation of target molecules by inhibiting class I-II HDACs in lymphoma cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: SU-DHL-4, OCI-LY1, SU-DHL-2, and U2932 cells Concentration: 1 nM-10 μM Incubation Time: 72 hours Result: Potently reduced cell viability in all four lymphoma cell lines in a concentration-dependent manner. Western Blot AnalysisCell Line: SU-DHL-4 and OCI-LY1 cells Concentration: 10 nM, 30 nM, 100 nM, 300 nM Incubation Time: 24 hours Result: Decreased the expression of BCL-6 as well as BCL-2 in cells.

In Vivo

Alteminostat (CKD-581; 20-40 mg/kg; ntraperitoneal injection; twice a week; for 4 weeks) treatment partially but significantly suppresses tumor growth in SU-DHL-4 xenograft mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male NOD.CB17 SCID injected with SU-DHL-4 cells Dosage: 20 mg/kg or 40 mg/kg Administration: Intraperitoneal injection; twice a week; for 4 weeks Result: Partially but significantly suppressed tumor growth.

Form:Solid

Specifications

Specifications & Purity

≥98%

Biochemical and Physiological Mechanisms

Alteminostat (CKD-581) is a potent HDAC inhibitor. Alteminostat inhibits the class I-II HDAC family via histone H3 and tubulin acetylation. Alteminostat can be used for lymphoma and multiple myeloma research.

Storage

Protected from light, Store at -20°C

Shipped In

Ice chest + Ice pads

This product requires cold chain shipping. Ground and other economy services are not available.

Action Type

INHIBITOR

Purity

≥98%

Names and Identifiers

• Isomeric SMILES: CN1CCN(CC1)C(=O)N(CCCCCCC(=O)NO)C2=CC=C(C=C2)C3=CC4=C(C=C3)C=NN4C
• PubChem CID: 58074180
• Molecular Weight: 492.61

Chemical and Physical Properties

• Molecular Weight: 492.600 g/mol
• XLogP3: 2.800
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 5
• Rotatable Bond Count: 9
• Exact Mass: 492.285 Da
• Monoisotopic Mass: 492.285 Da
• Topological Polar Surface Area: 93.900 Ų
• Heavy Atom Count: 36
• Formal Charge: 0
• Complexity: 708.000
• Isotope Atom Count: 0
• Defined Atom Stereocenter Count: 0
• Undefined Atom Stereocenter Count: 0
• Defined Bond Stereocenter Count: 0
• Undefined Bond Stereocenter Count: 0
• The total count of all stereochemical bonds: 0
• Covalently-Bonded Unit Count: 1